NCT00080665View on ClinicalTrials.gov

Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2011

Conditions
Breast Cancer
Interventions
DRUG

docetaxel

Docetaxel (15-30 mg/m2, IV, weekly on days 1, 8, and 15) each 28 day cycle

DRUG

imatinib mesylate

Imatinib mesylate (400-600 mg, oral, once daily) each 28 day cycle

Trial Locations (1)

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00080665 - Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter